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1. Περί ληψη 
Tα microRNA είναι μικρά μη-κωδικά ολιγονουκλεοτίδια μήκους περίπου 20-25 ζευγών 
βάσεων. Ρυθμίζουν την γονιδιακή έκφραση στο μετά-μεταγραφικό επίπεδο μέσω της 
πρόσδεσης τους στα μετάγραφα στο κυτταρόπλασμα. Η πρόσδεση εξαρτάται από την 
συμπληρωματικότητα των δύο νουκλεϊκών οξέων. Η PARN (PARN, EC 3.1.13.4) είναι μία 
υδρολάση που δρα σε εστερικούς δεσμούς και παράγει 5’-φωσφομονοεστέρες. Ειδικότερα, 
η PARN είναι μια αποαδενυλάση που αποικοδομεί ειδικά τις πολυ(Α) ουρές των mRNAs με 
κατεύθυνση 5΄- 3΄. Η PARN είναι πολύ σημαντική για την αποικοδόμηση των mRNAs στα 
ευκαρυωτικά κύτταρα και για την σωστή ανακύκλωση των mRNAs. Η PARN μπορεί πιθανά 
να δρα και ως ογκοκατασταλτικός παράγοντας προκαλώντας την αποικοδόμηση των 
mRNAs της IL-8 και του VEGF. Tα miRNA αποτελούν επίσης παράγοντες-κλειδιά στην 
ρύθμιση της ανακύκλωσης των mRNA. Με την αλληλεπίδραση τους μέσω της 
συμπληρωματικότητας αφενός παρεμποδίζουν την μετάφραση αφετέρου προκαλούν την 
αποικοδόμηση του mRNA στόχου προσελκύοντας ριβονουκλεάσες, όπως η PARN. Στην 
παρούσα μελέτη εξετάζουμε πως η PARN ρυθμίζεται από τα miRNAs. Εξετάσαμε το ρόλο 
των miR-29a-3p και miR-1207-5p  στην έκφραση της PARN. Παρατηρήσαμε πως τα εν 
λόγω miRNAs έχουν την ικανότητα να προσδένονται στην 3’ αμετάφραστη περιοχή της 
PARN και να προκαλούν μείωση της εκφρασης της. Πιστοποιήσαμε τις αλληλεπιδράσεις 
μέσω της παραγωγής μεταλλαγμάτων της 3’ αμετάφραστης περιοχής της PARN για τις 
θέσεις πρόσδεσης των miRNA.   
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1. Abstract 
MicroRNAs (miRNA) are small non-coding oligonucleotides of about 20-25 base pairs in 
length. They have the ability to regulate gene expression at the post-transcriptional level 
by binding onto transcripts in the cytoplasm in sequence specific manner. Poly(A)-specific 
ribonuclease (PARN, EC 3.1.13.4) is a hydrolase that acts on ester bonds and produces 
5’-phosphomonoesters. Specifically, PARN is a deadenylase that degrades the poly(A)-
tails of the m-RNAs with a 5’-3’ direction. PARN is very important for the degradation of 
mRNAs in the eukaryotic cells and for the correct turnover of the mRNAs. PARN can 
potentially act as a tumor suppressor causing degradation of IL-8 and VEGF mRNAs. 
miRNAs are also key players in the regulation of miRNA turnover. With a sequence 
specific manner they can prevent translation or even degrade their target mRNA. In this 
later step of degradation miRNAs can recruit ribonucleases, like PARN, to help them 
degrade the transcripts. In this study we examine how PARN is being regulated by 
miRNAs. We examined how the expression of PARN is regulated under the influence of 
miR-29a-3p and miR-1207-5p. We were able to notice that these two miRNAs have the 
ability to bind to the 3’ UTR of PARN and cause the decrease in the expression levels. We 
verified also these interactions by creating mutants of the original 3’ UTR for the sites for 
the miRNAs.  
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2. Introduction 
2.1. microRNAs  
 
MicroRNAs (miRNA) are small non-coding oligonucleotides of about 20-25 base pairs in 
length. They have the ability to regulate gene expression at the post-transcriptional level 
by binding onto transcripts in the cytoplasm in sequence specific manner. The actual 
repression occurs wither by degradation of the target transcript or through inhibition of the 
translational process. They were discovered two decades ago by Ambros et al1 and 
changed the focus of the scientific community from the classical central dogma of 
biochemistry2. For the first time the focus was turned over to non-coding genes and in the 
next twenty years our knowledge around miRNAs and the biological role has expanded 
and keeps giving us new insights.  
The first miRNA was found in C. elegans. Ambros and colleagues discovered lin-4 a gene 
that was found to encode for the production of two small RNAs which also are 
complementary to the 3’ untranslated region of lin-14 mRNA1. One of these transcripts was 
61 base pairs long and found to create a stem loop and the other was about 21 
nucleotides long. It was also found that the levels of the LIN-14 protein were reduced when 
these RNAs were present and allowed the larva to proceed from developmental stage 1 to 
2. These discoveries suggested that there was an RNA-RNA interaction that caused this 
specific post-transcriptional suppression of lin-141.  
Seven years later in 2000 let-7 become the second miRNA to be discovered by Reinhart et 
al again in C. elegans2,3. It was characterized as a 21 nucleotide long RNA that controlled 
the L4 to adult transition of the larva. The remarkable in this case is the discovery that let-7 
is conserved across species, even in humans, and triggered the quest to find other 
molecules like that and also upgraded the importance that miRNAs may have and their 
role2.  
Nowadays it is known that miRNAs represent almost 1% of the genome of many species 
and estimations show that 30% of our genes are regulated by at least one miRNA4,5. 
Current release 20 of miRBase6, a database hosted by the University of Manchester and 
supported by the Welcome Trust Sanger Institute, hosts 24,521 entries of predicted hairpin 
structures of miRNAs and provides information such as the position and the sequence. 
 
 
2.2. microRNAs biogenesis and role in cancer 
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MiRNAs are dispersed along our genome and as already stated before they represent 
about 1% of our genome. The genes that produce miRNAs can be found as single genes 
or as clusters that can either be transcribed independently from one another or as 
polycistronic transcripts. Furthermore the genes can also be part of the introns of a gene 
that transcribes for the mRNA. 
MicroRNA biogenesis is a process that involves many stages of maturation. The birth of 
miRNAs takes place in the nucleus where miRNA genes transcribe and produce one long 
transcript. This is called pri-miRNA and is the primary precursor of the final about 21 base 
pair long miRNA2. Pri-miRNA is both 3’ adenylated and bears a 7-methylguanosine cap7. 
The transcription is carried out by RNA-
polymerase II and rarely by RNA-polymerase 
III7–9. The transcript that is created can 
contain only one miRNA but can in some 
cases be polycistronic and contain the 
sequences of more than one miRNAs. The 
transcription is also under the control of 
transcription factors of the cell and of the 
methylation of the promoters10–12. 
Then it is time for Drosha to process the pri-
miRNA and to allow it to proceed to the next 
step. Drosha is a class 2 RNase III enzyme 
and is part of the Microprocessor complex 
along with the dsRNA binding protein DGCR813. After this the transcript is now the 
precursor pre-miRNA and has a hairpin 
structure of 60-110 nucleotides in length2,13. It 
also now has a 2 nucleotide overhang in the 3’ due to its cleavage from an RNase III13. 
The last step for the pre-miRNA in the nucleus is their transfer to the cytoplasm. in this 
step the processed transcript uses the RanGTP/exportin 5-dependent mechanism14–16. It 
has been stated in the literature that for the export from the nucleus the ends created in 
the previous step from Drosha may facilitate a better interaction between the miRNA and 
the exportin complex15. However it is worth to note that there are also some miRNAs that 
contain special sequences that imply their sub cellular localization as shown in 2007 by 
Figure 1 miRNA biogenesis
66
. 
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Hwang et al17. In some cases some miRNAs contained signals that led them back to the 
nucleus. 
In the cytoplasm the transcript has to undergo some more modifications in order to 
become mature. The first step is the cleavage from another RNase III. This time it is Dicer-
1, together with 
TRBP/PACT proteins, that 
will cleave the pre-miRNA 
hairpin in an imperfect 
RNA duplex of about 20-
21 nucleotides long18–20. 
Finally the duplex will be 
unwound by a helicase 
into a one stranded 
mature miRNA that is 
ready to proceed to the 
next stage and be used by 
the cell mechanism in 
order to induce its effect21. 
We have to note that from 
the helicase reaction two 
possible miRNAs normally 
are created but eventually 
only one is being chosen 
and loaded onto the RNA-
induced silencing 
complex. Usually the 
strand with the most 
unstable base pair on its 5’ 
end is the one loaded as it 
is stated in the 
literature22,23. 
Deregulation can be noticed in many different levels of the biogenesis pathway of miRNAs. 
Just like protein-coding genes in cancer a miR-gene can be deregulated in many different 
ways. In this thesis we will only provide a quick view to all these mechanisms.  
Figure 2 Figure of the miRNA biogenesis and action pathway enriched with all the 
possible changes that could lead to miRNA deregulation in the organism in the case 
of cancer. (A) shows deregulation in the gene level. (B) deregulation in the biogenesis 
process or during the canonical pathway. (C) mechanisms with witch cancer can 
allow the cell to skip the regulation of miRNAs26. 
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First in the list are mutations of the miRNA. It is easily understandable that a mutation of 
the seed site of the mature miRNA could cause the complementarity loss and thus inhibit 
the control of a oncogene. 
Cancer cells undergo a series of epigenetic changes like hyper-methylation etc24. Lots of 
miR-genes have been found to be associated with CpG islands and so epigenetics could 
alter the expression of miR-genes in cancer25. miRNA expression can be affected by the 
presence or absence of transcription factors. Oncogenic factors like Myc have been found 
to cause the suppression of tumor-suppressing miRNAs. Respectively transcription factors 
that are tumor-suppressors usually induce the biogenesis of miRNAs that enable tumor-
suppression. In cancer many of these factors are no longer expressed and so the 
expression of these miRNAs is also deregulated. 
Another way to deregulate miRNAs is by mutations in the biogenesis pathway. As we 
discussed before the biogenesis of miRNAs is a complex pathway that includes many 
proteins and many steps to complete. A mutation that causes loss of function in such a 
protein can lead to a problem in the biogenesis of miRNAs and thus can result in no 
miRNA production26–28. 
The reason for the loss of regulation can also be the target: a mutation could create an 
isoform of the mRNA that for some reason (alternative splicing, point mutation) is no 
longer susceptible to the control of the miRNA26. 
 
2.3. microRNAs as therapeutic agents  
 
It is evident that miRNAs have the ability to regulate a large number of genes. It is also 
valid to think that many diseases are based on the deregulation of certain genes that 
cause the phenotype. So immediately we raise a point where miRNAs can be possibly 
manipulated in such way that we could use them to restore the normal condition. This 
thought exists in the literature already. There some trials in cell lines, rodents and non-
human primates that suggest that it may be possible to produce a certain phenotype and 
eventually lead us to new ways of fighting diseases29–32. The uses seem to have a broad 
range from obesity to cancer and even to viral infections33. 
Another approach is to use miRNAs as biomarkers2. That can either help us distinguish 
people in healthy and disease groups or can be used as markers of the progression of a 
disease. Special interest exists in miRNAs in the serum since it is a non-invasive sample 
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that is easily received from patients2. Especially about cancer certain deregulations of 
miRNAs in the plasma have been reported in the literature34–37. 
 
2.4. PARN and its role in cancer 
 
Poly(A)-specific ribonuclease (PARN, EC 3.1.13.4) is a hydrolase that acts on ester bonds 
and produces 5’-phosphomonoesters. PARN  gene is located on chromosome 16p13.The 
human protein is a homodimer and has high specificity for poly(A) tails. This specificity 
comes from the residues of the active site and the nucleotides around the actual acting 
site regulate the efficiency of the 
enzyme. It has 639 amino acids and 
weighs 74 kDa38. PARN acts as a 
homodimer and its active site consists of 
four acidic amino acids Asp28, Glu30, 
Asp292, and Asp38239–41. The amino 
acids that form the active site are also 
characteristic of the family of the 
enzyme. PARN is part of the RNase D 
family which is part of the DEDD 
superfamily39–41. The formation of the 
homodimer is essential for the catalytic 
activity of the enzyme42,43. It has 3 
domains: the catalytic nuclease, the R3H 
domain and the RNA binding domain42–44. 
PARN is very important for the 
degradation of mRNAs in the eukaryotic 
cells and for the correct turnover of the mRNAs. The step of deadenylation is crucial for 
the 3’5’ decay. Besides this PARN plays a role in Non-sense Mediated Decay (NMD)45 
of transcripts that contain a premature stop codon, in the maturation of oocytes46–48, in the 
embryonic development49, in the degradation of unstable mRNAs rich in AU50 and in DNA 
repair51,52. It is an enzyme highly conserved among many eukaryotes. Another unique 
feature of PARN is the fact that is the only deadenylase that interacts not only with the 
Figure 3 The 3D structure of the nuclease domain of PARN from 
Protein Data Bank Database 
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poly(A) tail but also with the m7G-cap. PARN also plays a role in the biogenesis of some 
miRNAs like miR-45153.  
The information on the biological role and the regulation of PARN in cancer is very limited. 
PARN can potentially act as a tumor suppressor causing degradation of IL-8 and VEGF 
mRNAs. Importantly, RBPs such as KSRP, tristetraprolin (TTP) and CUG-BP may recruit 
PARN to destabilize various mRNAs, including c-jun, uPA, c-fos and TNF mRNAs, the 
elevations of which are implicated in cancers54. Recent work has shown that the 
expression of several deadenylases in altered in acute leukemias, while PARN may 
represent a promising biomarker55. Further, preliminary results from the lab of Mr. Nikolaos 
Balatos’ lab from pathological samples suggest that PARN and several deadenylases are 
differentially expressed in lung cancer subtypes, including squamous cell carcinoma and 
small cell lung cancer.  
 
2.5. mRNA stability 
in cancer and miRNA 
mediated 
deadenylation 
 
One of the hallmarks of cancer 
is the mRNA instability. In many 
cancers abnormalities in the 
regulation of gene expression 
and mRNA stability are 
present54. Normally the 
degradation of the transcripts in 
the cells are under strict control 
through cellular signals56–58. 
Studies in the last decade have 
shown that this deregulation is 
not only part of amplifications, 
deletions or problems in critical 
cellular processes but can be 
also due to components of the 
post-transcriptional 
mechanism54. Cis-acting and 
Figure 4 Modes of action for trans-acting factors. (A) Non-coding RNAs can 
regulate mRNA translation and degradation. Top: Argonaute 2 (Ago2) is 
induced to cleave mRNAs with externally introduced short interfering RNAs 
(siRNAs). However, a near to perfect complementary hybridization of 
miRNAs to mRNAs can also induce Ago2, complexed with other gene 
silencing machineries, to cleave the target mRNA. Bottom: miRNAs, a 
subclass of non-coding RNA, can inhibit the translational process while 
recruiting the RNA decaying machineries such as deadenylases and 
decapping enzymes. (B) RNA-binding protein (RBP) controls the stability of 
mRNAs. (C) Ribonucleases (RNases) can act alone or in concert with other 
decaying factors to destine mRNAs for degradation. Deadenylases such as 
Poly A Ribonuclease (PARN) and CCR4b from CCR4b–NOT complex 
remove the Poly A tail of the target mRNA, while decapping enzymes remove 
the 5′-m7G mRNA cap. Endoribonucleases can cleave mRNA in the middle of 
mRNA sequence. The combinations of these three processes make mRNA 
available for exoribonucleases to further degrade and clear the transcript in 
5′–3′ (XRN1) or in 3′–5′ direction (Exosome complex)54. 
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trans-acting elements may play a 
role especially in the degradation 
of the mRNA. In this context non-
coding RNAs like miRNAs and 
ribonucleases like PARN may be 
implicated in the process of 
tumorigenesis. 
For miRNAs the main mode of 
action is their interaction with the 
3’ UTR of the mRNA. Through 
the complementarity between the 
miRNA and the mRNA proteins of 
the Argonaute family (Ago) are 
recruited forming a complex with 
the miRNA inhibiting translation54. 
In some cases of almost 
complete complementarity the 
result can be the endonucleolytic cleavage of the transcript. Of all the members of the 
Argonaute family only Ago2 has been found to have the ability to induce this cleavage 
through its RNase H domain59,60. miRNAs can also induce degradation of the mRNA 
through a deadenylation-dependent manner or independent exonucleolytic pathway, or by 
unidentified decay factors as show in figure 5 A through the recruitment of deadenylases 
like CCR4b54. Especially about deadenylation induced by miRNAs, they recruit the miRNA-
induced silencing complex (miRISC), which includes Argonaute and GW182 as core 
proteins61. GW182 proteins effect translational repression and deadenylation of target 
mRNAs. GW182 independently tethers two deadenylase machineries (CCR4–NOT and 
PAN2 and PAN3) by means of independent motifs and has a newly identified role as a 
deadenylase coactivator in the processive deadenylation of mRNA targets61. Firstly, 
GW182 serves as a binding platform that recruits two deadenylase complexes to target 
RNAs. Secondly, GW182 acts as a deadenylation coactivator by assisting the CCR4–NOT 
complex to shorten the poly(A) tail61. 
Moreover RNA binding proteins can affect mRNA stability. These proteins have the ability 
to bind on the transcripts either on the 3’UTR or the coding region and regulate the 
Figure 5 GW182 binds Argonaute (AGO) through its N-terminal GW-rich 
domain to form the miRISC. GW182 recruits the poly(A) tail into the 
vicinity of the miRISC by interacting with PABP through the PAM2/PABC 
contact. Two CCR4–NOT interaction motifs (CIMs) in the GW182 recruit 
the CCR4–NOT complex to facilitate deadenylation of miRNA-targeted 
mRNAs. CIM-1 and CIM-2 are labeled with their coordinates in the human 
GW182 paralog TNRC6C. The CNOT1 subunit interaction with GW182 is 
depicted with two-sided arrows. The PAN2–PAN3 interaction with PABP 
has been purposely excluded to simplify the figure.61 
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degradation rate of a transcript62–64. Depending on the protein, as shown in figure 5 B, the 
effect can be destabilization, through the recruitment of ribonucleases, or stabilization of 
the transcript through inhibition of the action of these enzymes. 
mRNA stability and degradation can be regulated by the action of exoribonucleases65. 
They can induce the deadenylation of the transcript and the degradation from the 3’ to the 
5’ end: PARN is protein that can act in this way. Moreover the removal of the cap can 
allow exoribonucleases to digest the mRNA from 5’ to 3’ end. Finally endoribonucleases 
internally digest the transcripts. The resulting fragments are further degraded by 
exoribonucleases without requiring the deadenylation or the decapping step54. 
In cancer these mechanisms may be deregulated resulting in an abnormal regulation of 
the mRNA and altered turnover time. The result is a change in the levels of different 
transcripts in the cells. Some of these transcripts may act as oncogenes or tumor 
suppressors therefore the loss of the cells’ equilibrium can lead to tumorigenesis and 
cancer progression.  
 
Figure 6 Depending on the nature of the mRNA (oncogene or tumor supressor) the loss of mRNA regulation can lead to a 
prolonged exposure of the cell to factors that lead to the cration of a cancer cell
54
.  
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3. Aim of this study 
The aim of this study is to investigate the possible regulations of PARN by miR-29a-3p and 
miR-1207-5p. As mentioned before both miRNAs and PARN are considerable elements 
that allow the cell to control the expression of different transcripts at any time. These 
regulations are very important, especially for diseases like cancer that have their bases in 
deregulation of the cell cycle. Both of these miRNAs have been found to be deregulated 
when PARN is silenced. They also seem to have the ability to silence PARN proposing 
that a certain feedback loop may be present. We tried to investigate if there is really such 
an interaction between the enzyme’s mRNA and the miRNAs. The study was part of my 
ERASMUS scholarship and was conducted at the Laboratory of RNA Biology and 
Biotechnology of the University of Trento, Italy. 
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4. Materials and methods 
4.1. Bioinformatics analysis  
 
From miRBase and Genome Browser we downloaded the sequence of our miRNAs and 
PARN’s 3’ UTR respectively. That way we were able to work in silico and predict target 
sites. 
Using the PITA algorithm, software provided by Segal Lab of Computational Biology, on 
the 3’ UTR of PARN we were able to identify 4 positions for our miRNAs of interest. 
Subsequently we entered the FASTA format of our 3’ UTR and our miRNAs in the 
RNAHybrid tool and tried to identify the exact 7-mer or 8-mer of the binding region. We 
managed to locate seeds on all of the PITA predicted sites. Thanks to these information 
we could now divide the 3’ UTR region into fragments, which were transfected into HeLa 
cells, containing our target sequences. 
  
4.2. Plasmids  
 
4.2.1. pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega) 
 
pmirGLO is a specially designed vector by Promega that allows us to detect and measure 
the activity of the miRNAs by cloning our 
target 3´ of the firefly Luciferase gene 
(luc2). Firefly Luciferase is the primer 
reporter gene that will actually indicate if 
there is a reduction of signal. This vector 
also expresses the Renilla Luciferase 
(hRluc-neo), which is used to normalize 
the results. In Figure 6 you can see the 
map of the vector. The PGK promoter of 
the Firefly Luciferase offers the ability to 
have a more sensitive analysis than by 
the use of a strong promoter. 
 
 
 
4.2.2. psiUX Vector 
 
Figure 7  pmirGLO vector 
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This vector was available in the 
RNA Biology and Biotechnology. 
It contains the Amp gene for 
selection and the precursor 
region of the miRNAs of interest. 
The pri-miRNA is cloned between 
the promoter and the terminator 
of the human U1 small RNA, 
which is highly transcribed. The 
use of this vector allowed us to 
achieve a physiological 
production of the mature miRNAs inside our cells. 
  
4.3.  E.coli transformation  
 
For the transformation of E. coli DH5a competent and XL10 ultra competent cells we thaw 
them in ice for 10 minutes. During this time we add our DNA (10μl for a ligation reaction) to 
100μl of KCM buffer (100mM KCl, 30mM CaCl2, 50mM MgCl2) and keep in ice for 5 
minutes. We then add 100μl of competent cells to the KCM-DNA mixture and gently mix. 
We incubate in ice for 20 minutes. Afterwards we heat shock the cells by exposing them to 
a temperature of 42°C for 1 minute and subsequently put them in ice for 1 minute. We add 
800μl of Luria Broth and incubate at 37°C for 40 minutes in a shaking incubator with a 
speed of 140 rpm. After the incubation we spin our cells at 4000 rpm for 4 minutes to pellet 
them and remove 800μl of the mixture from the tube. We resuspend the cells in the 
remaining 200μl and plate 50-100μl of them on an appropriate plate. The plates are 
prepared using LB agar (Sigma) and ampicillin (50μg/ml). Plates are incubated overnight 
at 37°C and the next day a solid colony is picked up and inoculated in Luria Broth. 
 
4.4. Plasmid DNA extraction  
 
For the plasmid DNA extraction we used QIAGEN Plasmid Maxi Kit and QIAprep Spin 
Miniprep Kit. With the Maxi Kit we were able to extract plasmid DNA in high concentrations 
Figure 8 psiUX vector
67 
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from bacterial cultures of about 200 ml. The basis of the extraction is the anion-exchange 
tips for purification of transfection-grade plasmid DNA from the lysate of the bacterial cells. 
For the Maxi Kit we pellet the cells at 6000 x g for 15 minutes at 4°C and treat them with 
the 10ml of buffer P1 that is given with the kit, this allows us to resuspend the cells in an 
appropriate environment for the next steps. Then we add 10ml of the second buffer P2, 
which will induce the lysis of the bacterial cells, and we incubate for 5 minutes at room 
temperature. The addition of 10ml of P3 buffer results in the interruption of the lysis. After 
the neutralization we see the formation of debris from the cells like genomic DNA, proteins 
etc. We centrifuge for 5 minutes at 8000xg so that the debris precipitate and we get a clear 
lysate. We apply the lysate on the special syringe like column that is used to filter the 
lysate. We then add 2,5ml of the endotoxin removal buffer that is provided and incubate for 
30 min on ice. We then equilibrate the anion exchange column using 10ml of a low salt 
buffer that is provided (Buffer QBT). We apply the lysate and allow the gravital forces to 
empty the column. We wash using 30ml of medium salt buffer (Buffer QC) twice and finally 
we elute the plasmid in 15ml of high salt buffer (Buffer QN). Subsequently we precipitate 
DNA by adding 10.5 ml room temperature eluted DNA. Mix and centrifuge immediately at 
≥15,000 x g for 30 min at 4°C. This step is done in order to clean our DNA from the salt 
that is in the elution buffer. In the next step we wash the pelleted DNA with 70% ethanol, 
which removes precipitated salt and replaces isopropanol with the more volatile ethanol, 
making the DNA easier to redissolve. Finally we decant the supernatant and redissolve the 
DNA in 300μl of RNase DNase free water. 
For the Spin Miniprep kit the procedure is simpler and instead of gravital forces it uses a 
tabletop microcentifuge. We pellet the cells at 8000 rpm for 4 min and then resuspend 
them in 250μl buffer P1. Then we add 250μl of buffer P2 to induce the lysis of the cells. To 
neutralize the reaction and stop the lysis we add the provided buffer N3. To clear the 
lysate from the debris we centrifuge for 10 minutes at 12000 rpm. Subsequently we apply 
the supernatant to the columns that contain a specialized silica membrane on which our 
DNA is binding. We centrifuge at 12000 rpm for 1 minute and discard the flow-through. We 
wash two times with 0,5ml and 0,75ml of the provided buffers PB and PE respectively. 
After the addition of each of the buffer we centrifuge for 1 minute at 12000 rpm and discard 
the flow through. After the PE buffer we centrifuge once again to clean the column from 
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any residues. Finally we add 50μl of water in the center of the column and place it in a 1,5 
ml eppendorf. Centrifuge for one more minute to obtain our DNA. 
Table 1 Composition of buffers for plasmid extraction 
Name of 
buffer 
Composition 
P1 50 mM Tris-HCl pH 8.0, 10 mM EDTA, 100 μg/ml RNaseA 
P2 200 mM NaOH, 1% SDS 
P3 3.0 M potassium acetate pH 5.5 
Buffer QBT 
750 mM NaCl, 50 mM MOPS pH 7.0 ,15% isopropanol, 0.15% triton X-
100 
Buffer QC 1.0M NaCl, 50 mM MOPS pH 7.0, 15% isopropanol 
Buffer QN 1.6M NaCl, 50 mM MOPS pH 7.0, 15% isopropanol 
Buffer N3 4.2 M Gu-HCl, 0.9 M potassium acetate, pH 4.8 
Buffer PB 5 M Gu-HCl, 30% isopropanol 
Buffer PE 10 mM Tris-HCl pH 7.5, 80% ethanol 
 
4.5. Cloning 
 
Thanks to the bioinformatic analysis we had the ability to proceed with the cloning of the 3’ 
UTR of PARN. We cloned the total 3’ UTR and some fragments that we chose with our 
bioinformatic tools. First we had to design the primers for our region of interest. These 
primers are shown below along with a scheme of the 3’ UTR of PARN and the relative 
location of our chosen fragments on it. Before amplifying anything we had to check the 
best annealing temperature for our primers. So we performed a PCR reaction using a 
PARN29a FOR ACTGGAGCTCCCAAGACCTGAGGGCAGCAA 
PARN29a REV ACTGCTCGAGCAGGAGACAACTTGGTTTCC 
PARN1207 5p FOR ACTGGAGCTCCTGCTGTGATCATGAATTTG 
PARN1207 5p REV ACTGCTCGAGAAGGACAAGCTTGAGAGCGT 
PARN1207 5p-29a FOR ACTGGAGCTCCATGGGGGATGTACGAGTAA 
PARN1207 5p-29a REV ACTGCTCGAGTGCTGTGATCTGTTTCAACG 
PARN tot REV ACTGCTCGAGGTCCTATGAAAATGTTTTTA 
 
Table 2 PCR primers for the amplification of the 3' UTR of PARN and fragments. Green indicates the restriction site for 
SacI-HF® and yellow for XhoI. Direction 5’3’ 
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temperature 
 
Figure 9 The relative positions of the fragments we created on the 3' UTR of PARN. In the grey rectangles you see the 
relative positions of the miRNA sites on the 3' UTR 
gradient (48,2°C-66°C) and set up multiple reactions in order to run them on an agarose 
gel and check the results. For this reaction the protocol was this: 
Table 3 PCR mix for the temperature gradient reaction volumes and protocol 
Reagents 1x Run 
dNTP’s 0,5 μl 5:00 minutes 95°C 
0:30 seconds 95°C 
0:40 seconds 66°C-44°C 
1:00 minute 72°C 
Repeat x34 
5:00 minutes 72°C 
12°C Infinite 
Reaction Buffer 10x 3 μl 
RBC polymerase 0,3 μl 
Genomic DNA 1,5 μl 
Primer FOR 1 μl 
Primer REV 1 μl 
Water 22,7 μl 
Total 30 μl 
The 30 μl reaction is separated in 10 μl smaller reactions and run in three different 
temperatures 48,2°C, 57,3°C and 64,2°C. This same reaction mix was used for the 
amplification of the 3’ UTR in the ideal temperature for the primers. All the PCR products 
were checked by electrophoresis on an 1,5% agarose gel.  
After the amplification we use a QIAGEN commercial kit for the purification of the PCR 
product. DNA adsorbs to the silica membrane in the presence of high concentrations of 
salt, while contaminants pass through the column. Impurities are efficiently washed away, 
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and pure DNA is eluted with water. Then the purified DNA from the PCR and our vector 
(pGLO) is restricted by the two enzymes of choice SacI-HF® and XhoI. For the restriction 
reaction we used: 
Table 4 Restriction mix for 3' UTR and vector 
Reagents PCR products Vector Protocol 
Reaction Buffer 10x 5,6 μl 5 μl 37°C for 3 hours 
XhoI 1 μl 1 μl 
SacI-HF® 1 μl 1 μl 
DNA The whole purified 
PCR product 
10 μl of a 1478 
ng/μl 
Water - 33 μl 
Then we purify again using the same kit to clean our DNA from any chemicals or enzymes 
that could possibly inhibit our ligation reaction. For the ligation we used the following 
protocol: 
Table 5 Ligation mix and protocol 
Reagents 1x Protocol 
Reaction Buffer 10x 2 μl Overnight incubation at 
room temperature and 
protected from light 
T4 DNA ligase 1 μl 
3’ UTR of PARN 35 ng 
Vector 1 μl of a special dilution 100 
ng/μl 
Water Until total volume 20 μl 
After the incubation we used 10 μl of the reaction to transform DH5α cells as discussed 
above. 
 
4.6. Site directed mutagenesis 
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For the site-directed mutagenesis we used the kit QuikChange® II XL from Stratagene®. 
For the mutagenesis the first and most important step was the design of the special 
primers that would allow us to cause the specific mutation. In our case the target was to 
eliminate the seed sequence of the miRNAs from the 3’ UTR of PARN. The primers had to 
fulfill certain criteria such as length of 25-45 base pairs, the mutation has to be in the 
middle of the sequence, melting temperature  75°C and a minimum of 40% of GC 
content. We addressed successfully all of the prerequisites and the primers that were used 
are shown below. Notice that each of the miRNAs we test, 29a and 1207, have 2 sites on 
our 3’ UTR that are of interest and so we created a set of primers for the elimination of 
both of these sites. 
After the primers we set up the reaction for the mutagenesis according to the provided 
manual. Once again a table below shows the reagents used and the protocol. The basis of 
this kit is that the oligonucleotide primers, each complementary to opposite strands of the 
vector, are extended during temperature cycling by PfuUltra HF DNA polymerase, without 
primer displacement. Extension of the oligonucleotide primers generates a mutated 
plasmid containing staggered nicks. Following temperature cycling, the product is treated 
with Dpn I. The Dpn I endonuclease is specific for methylated and hemi methylated DNA 
and is used to digest the parental DNA template and to select the mutated plasmid over 
the template. DNA isolated from almost all E. coli strains is dam methylated and therefore 
susceptible to Dpn I digestion. The vector that remains incorporates the desired mutations 
is then transformed into XL10-Gold®*** ultracompetent cells following the same protocol 
as discussed above. The amount of μl needed each time for DNA and primers was 
calculated after diluting and measuring with the Nanodrop ND-1000. 
1st position for Δ29a FOR GCAGCAAACCGGTCGCTGTGAGCAAGAGC 
1st position for Δ29a REV GCTCTTGCTCACAGCGACCGGTTTGCTGC 
2nd position for Δ1207 FOR CGGTTGTGCCTCCCACCATAGCTGCC 
2nd position for Δ1207 REV GGCAGCTATGGTGGGAGGCACAACCG 
3rd position for Δ29a FOR CTGTTCTTATGCGTGTTCACTTTCCAGAG 
3rd position for Δ29a REV CTCTGGAAAGTGAACACGCATAAGAACAG 
4th position for Δ1207 FOR CGTGCAAATCTACAACATGCATTCTCCG 
4th position for Δ1207 REV CGGAGAATGCATGTTGTAGATTTGCACG 
 
Table 6 Primers for the site-directed mutagenesis. Direction 5'3' 
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Figure 10 The principle of the mutagenesis protocol 
Table 7 Site-directed mutagenesis reaction volumes and protocol 
 
4.7. Sequencing 
Reagents Volume 1x Protocol 
Reaction Buffer 10x 5 μl 95°C 1 minute 
18 cycles: 
95°C 50 seconds 
60°C 50 seconds 
DNA template 10 ng 
Primer FOR 125 ng 
Primer REV 125 ng 
dNTP’s 1 μl 
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For sequencing of our plasmids we used BMR 
genomics an official spin-off of the University of 
Padova. To prepare the samples we used PCR 
tubes of 0.1ml and add 500ng of our plasmid along 
with the primer we use each time. For the fist part 
of this project and the cloning of 3’ UTR of PARN 
we used a special primer that binds to the luc gene 
of our plasmid right before our area of interest. For 
the second part of the mutagenesis we checked some of the constructs using this same 
primer and the rest were checked using another primer that bound approximately half-way 
along the 3’ UTR of PARN. Below you can see the sequences of these two primers. 
 
4.8. Cell line  
 
Our cell line of choice is HeLa. HeLa cells are easy to grow and to transfect. It is a cell line 
derived from human cervix tumor of a 31 year old black person. Their ability to be immortal 
is based on the expression of an active telomerase during the cell division stage. They 
form a monolayer of cells inside the flask that they grow. The conditions in the incubator 
are 37°C, air 95% and 5% CO2. The base medium for this cell line is Eagle's Minimum 
Essential Medium (Gibco) with the addition of 1% glutamine, 10% fetal bovine serum and 
1% Penicillin Streptomycin (Pen Strep). For long-term storage we use liquid nitrogen vapor 
phase.  
HeLa cells have a doubling time of about 24 hours. Subculturing was done 2 times per 
week every 3 days. To do this we had to follow these steps: 
 Under the microscope we check that the confluence of our flask is above 90% 
QuikSolution™ 3 μl 68°C 7 minutes 
Finally: 
68°C 7 minutes 
Water Until final volume is 50 μl 
LUC2 FOR SEQ CATCGCCGTGTAATAAT 
PARN1207 5p-29a FOR ACTGGAGCTCCATGGGGGATGTACGAGTAA 
 
Table 8 Primers used for sequencing our cloned fragments from pGLO vector 5’3’ 
Figure 11 HeLa cells in high density 
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 Aspirate the medium and wash twice with Phosphate-Buffered Saline (PBS) 
 Add 1ml of trypsin (EDTA 1%) 
 Place the cells in the incubator and wait for 2 minutes 
 Observe that the cells are detached 
 Add 9ml of DMEM with glutamine and Pen Strep antibiotic 
 Using a pipette of 10ml mix the cells by pipetting up and down to break any clumps 
 Put 2ml of your previous cell culture in a new flask containing 16ml of DMEM in a 
dilution 1:8 
 
4.9. Transfection 
 
For the transfection of our eukaryotic cells we use the MIRUS TransIT®-LT1 transfection 
reagent. The protocol requires the use of two solutions. The first solution, from now on 
solution A, contains the DNA we wish to transfect and opti MEM®. The second solution, 
from now on solution B, contains opti MEM® and the transfection reagent. This second 
solution can be common for all the conditions whereas solution A has to be unique for 
each condition. In our experiments we performed co-transfections of HeLa cells with two 
plasmids. The one plasmid was the pGLO vector (Promega) where we had cloned our 3’ 
UTR as a whole or in fragments, downstream the Luciferase gene, and the other one was 
the pSiUx vector that was used in order to over express our miRNAs in the cells. For each 
condition we used 50ng and 500ng of plasmid respectively per well. For solution A also we 
calculated the amount of opti MEM® by considering that we needed 30μl of solution A per 
well. For solution B the amount of opti MEM® was calculated by multiplying by the number 
of wells the amount of solution B that was needed per well, that is 20μl. In the solution B 
we also had to add our transfection reagent. The amount of MIRUS required was 3μl of 
transfection reagent for every 1000ng of DNA used in the co-transfection. When all 
solutions were prepared we mix them and incubate at room temperature for 20 minutes. 
Subsequently we add 50μl of the mixture to each well. MIRUS does not require a change 
of medium like other reagents because it is not toxic to the cells. 
For every transfection we tested our conditions on 24 and 48 hours. The amount of cells 
used in each set of conditions was different. For the 24 hours we used 60000 cells and for 
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the 48 hours we used 50000 cells. The cells were put in a 24-well plate one day before the 
transfection so that they could attach to the surface of the plate. In order to have no 
interference with our results on the Luciferase assay we used DMEM White with 1% 
glutamine for the transfection. 
 
4.10. RNA extraction 
 
For the RNA extraction from HeLa cells we used TRIzol® reagent from Life Technologies. 
TRIzol® Reagent is a monophasic solution of phenol, guanidine isothiocyanate, and other 
proprietary components which facilitate the isolation of RNA either large or small molecular 
size. TRIzol® Reagent maintains the integrity of the RNA due to the inhibition of RNase 
activity while disrupting cells and dissolving cell components during sample 
homogenization.  
For our protocol we use cells that grow on a 24-well plate. We first remove the medium 
and clean the well using 500 μl Phosphate Buffer Saline (PBS). We aspirate the PBS and 
add 50 μl of trypsin 1% EDTA. After an incubation of 2 minutes in the cell incubator the 
cells are detached from the plate. We then add 450 μl of DMEM with phenol red and 
glutamine, PenStrep and FBS. We resuspend the cells and transfer them in an eppendorf 
tube of 1,5 ml. We centrifuge for 10 minutes at 13000 rpm at 4°C to form a pellet. We 
discard the supernatant and store the pelleted cells at -80°C until the extraction. 
For the extraction protocol we add to the pelleted cells 300 μl of TRIzol® under the 
chemical hood and resuspend the cells. Incubate at room temperature for 5 minutes. Then 
we add 60 μl of Chloroform also under the chemical hood. We mix using vortex for 15 
seconds and incubate for another 5 minutes at room temperature. We then centrifuge for 
15 minutes at 12000 rpm 4°C. We carefully take only the upper phase (aqueous) from the 
tube. We must be careful not to touch the pink TRIzol® phase (organic) and the interphase 
that contains cell debris. We transfer the chloroform phase in a new tube and and 150 μl of 
isopropanol to precipitate the RNA. We mix fast using a vortex and incubate for 15 minutes 
at room temperature. After the incubation we centrifuge once again same speed and 
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temperature for 10 minutes this time. 
We carefully remove the supernatant 
isopropanol and add 300 μl of ethanol 
75%. In this step we wash the RNA 
pellet. Centrifuge again for 5 minutes 
and remove ethanol from the tube. 
We allow some time (5-10 minutes) 
for the pellets of RNA to air dry under 
the chemical hood while in ice. Finally 
we resuspend the pellets in 32 μl of 
double distilled water. We store the extracted RNA in -80°C.  
 
4.11. qRT-PCR for the detection of miRNAs 
 
For the quantitative real-time PCR we use the miRCURY LNATM Universal RT microRNA 
PCR Exiqon Kit. It is a kit based on the use of SYBR® green. The difference in this kit is 
that we have a universal reverse transcriptase cDNA synthesis. By universal we mean for 
all the miRNAs in the cell followed by a real-time PCR for the detection of the miRNAs of 
interest using as mentioned above SYBR® green.  
Table 9 Reverse transcription reaction and volumes 
The first part of the protocol requires the dilution of the RNA samples to a concentration of 
5 ng/μl using nuclease free water. We then create a working solution for all of our samples 
that will be divided in aliquots. The working solution has to remain in ice because it 
Reagents Volume 1x Protocol 
5x Reaction Buffer 2 μl 60 minutes at 42°C 
Heat-inactivate reverse 
transcriptase for 5 minutes at 
95°C 
Cool to 4°C 
Nuclease-free water 5 μl 
Enzyme mix 1 μl 
Template RNA (5 ng/μl) 2 μl 
Total Reaction volume 10 μl 
Figure 12 The diphasic solution of TRIzol and chloroform 
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contains the enzyme. The details about the mix are in the following table. The RNA is 
added last after the mix has been aliquoted.  
We mix the reaction gently and do a spin down and put in the thermocycler. 
From the cDNA prepared we perform a dilution of 1:80. We then prepare the real-rime 
PCR master mix. The reagents are shown in the following table along with the protocol 
used. Again the master mix is prepared for all the samples and then aliquoted. Only this 
time because of the specific sets of primers we prepare more than one master mix. Also 
the cDNA template is added last in the well after we dispense the mix. The real-time is 
conducted on 384-well plates. 
Table 10 Real-time PCR reaction volumes and protocol 
Reagents Volume 1x Protocol 
PCR Master mix 5 μl 95°C for 10 minutes 
40 cycles of: 
95°C 10 seconds 
60°C 1 minute and Melting 
curve 
PCR primer mix 1 μl 
cDNA template 4 μl 
Total Reaction Volume 10 μl 
For our calculations we used the 2-ΔΔCt method. This method relies on two assumptions. 
The first is that the reaction is occurring with 100% efficiency; in other words, with each 
cycle of PCR, the amount of product doubles. The second assumption of the 2−ΔΔCT 
method is that there is a gene (or genes) that is expressed at a constant level between the 
samples. This endogenous control will be used to correct for any difference in sample 
loading. For each sample, the difference in CT values for the gene of interest and the 
endogenous control is calculated (the ΔCT). Next, subtraction of the control-condition Δ 
CT from the treated-condition ΔCT yields the ΔΔCT. The negative value of this 
subtraction, the −ΔΔCT, is used as the exponent of 2 in the equation and represents the 
difference in “corrected” number of cycles to threshold. The exponent conversion comes 
from the fact that the reaction doubles the amount of product per cycle. 
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Figure 13 Steps of the ΔΔCt method 
4.12. Quantification of nucleic acids 
 
For the quantification of the nucleic acids we used the Nanodrop ND-1000 by Thermo 
Scientific. The NanoDrop ND-1000 UV-Vis Spectrophotometer enables highly accurate 
analyses of samples as small as 1µl. It has a full-spectrum UV-Vis absorbance analyses 
(220-750nm) for measuring absorbance of DNA, RNA, dyes, proteins and microbial cell 
culture OD. Only 1,5 µl of sample needed for the quantification. It has a large dynamic 
range: 2-3700 ng/µl of dsDNA. A single measurement takes only 10 seconds. 
 
4.13. Luciferase  
 
For the Luciferase assay we used the Promega Dual-Glo® Luciferase Assay System. 
Measures Firefly Luciferase and Renila Luciferase . The normalization of the Firefly with 
the Renila helps differentiate between specific and non-specific responses as well as the 
transfection efficiency. The protocol is done using the 24-well plate were the cells grow 
without the need to detach them and pellet them. We add 35μl of DMEM white with 1% 
glutamine to well and 35μl of the special Dual-Glo® buffer that contains the substrate for 
the Firefly Luciferase. We cover the plate because of the photosensitive reagents and 
shake them for about 20 minutes at room temperature. During this time the reagent will 
induce lysis of the cells. Immediately after the shaking we put 20μl of the lysate to 384-well 
plate. Using the TECAN Infinite® 200 we measure the luminescence. Subsequently we 
add to each well 20μl of the buffer that will serve as the substrate for the Renila. This 
reagent is made by diluting 100 times the Renila substrate of the commercial kit with the 
special Dual-Glo® Stop & Glo® Buffer. This reagent is quite sensitive to the light so we 
immediately cover our plate and incubate at room temperature for 20 minutes. After that 
time we are able to measure the activity of the Renila using again the TECAN Infinite® 
200.  
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Figure 14 The reactions of the two Luciferase s 
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5. Results & Discussion 
5.1. Overexpression of miR-29a and miR-1207 
 
First we validated the overexpression of miR-29a-3p and miR-1207-5p in HeLa cells. 
Following the protocol mentioned in material and methods we transfected HeLa cells using 
the miRNA-overexpressing pSiUx vectors provided by the lab. These vectors can produce 
miRNAs from both strands of the hairpin structure of the pre-miRNA. They can be 
distinguished by their names that indicate the strand that produces them (3p and 5p 
respectively). Therefore, we decided to use a qRT-PCR enabling us to monitor the 
overexpression of the miRNAs produced from both both the 5p and the 3p. The following 
figures (15-22) provide a graphic representation of our data. 
In most cases we were able to verify the overexpression with statistically significant 
results. As a control we used HeLa cells transfected with the empty vector, this means that 
the there is no genomic region for a miRNA cloned inside the vector. In particular, miR-29a 
seems to be overexpressed compared to our control. In most cases the overexpression of 
miR-29a is not gigantic mainly because our cell line (HeLa) already express a very good 
basal level of this miRNA. Therefore it is not possible to obtain a bigger overexpression. 
The levels of miR-29a are around 1.2 to 1.9 fold change during the 24 and 48 hours with 
the exception of miR-29a-5p that during 48 hours it has a fold change of 10. Our attention 
was drawn to the fact that miR-29a seems also to be overexpressed when we introduce 
the vector for the overexpression of miR-1207. To our knowledge this is probably because 
of some compensatory or defensive mechanism of the cells against the stress cause by 
the transfection process. The same thing happens with the overexpression of miR-29a 
where we observe an overexpression of miR-1207 especially the 3p. 
In general the transfection of miR-1207 achieved very good levels both in 24 and 48 hours 
with a minimum of 3.9 fold change to a maximum of 31. The most noticeable 
overexpression levels is achieved by miR-1207-3p where we see a very significant fold 
change of more than 30 in the first 24 hours. 
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Figure 15 Fold change in the expression levels 24 hours after transfection of HeLa cells with the overexpressing vector for the 
miR-29a. P-value was calculated using one-tailed unpaired t-test with equal variance. One star indicates P-value ≤ 0.05, two 
stars is ≤ 0.01. 
 
Figure 16 Fold change in the expression levels of miR-29a-5p 24 hours after transfection of HeLa cells with the 
overexpressing vector for the miR-29a.  
 
Figure 17 Fold change in the expression levels of miR-1207-3p 24 hours after transfection of HeLa cells with the 
overexpressing vector for the miR-1207.  
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Figure 18 Fold change in the expression levels of miR-1207-5p 24 hours after transfection of HeLa cells with the 
overexpressing vector for the miR-1207.  
 
Figure 19 Fold change in the expression levels of miR-1207-3p 24 hours after transfection of HeLa cells with the 
overexpressing vector for the miR-1207.  
 
Figure 20 Fold change in the expression levels of miR-1207-3p 24 hours after transfection of HeLa cells with the 
overexpressing vector for the miR-1207.  
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Figure 21 Fold change in the expression levels of miR-1207-3p 24 hours after transfection of HeLa cells with the 
overexpressing vector for the miR-1207. 
 
Figure 22 Fold change in the expression levels of miR-1207-3p 24 hours after transfection of HeLa cells with the 
overexpressing vector for the miR-1207.  
As a result we can say that our system worked as far as the overexpression of the miRNA 
is concerned. This enabled us to proceed further with our experiments. 
 
5.2. PARN 3’ UTR cloning  
 
For the purposes of our project we decided to clone the 3’ UTR of PARN and fragments of 
it in the pmirGLO vector. Through this vector we would be able to measure the levels of 
the Luciferase activity and understand if there is any interaction between the 3’ UTR and 
our miRNAs. For this purpose we designed specific primers, as shown in the materials and 
methods section, for the amplification of the region from genomic DNA. As mentioned we 
also created smaller fragments of our 3’ UTR. In the first fragment there is one site for the 
miR-29a-3p, in the second fragment there is a site for miR-1207-5p and in the last 
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fragment there are two sites, one for each of our miRNA. These last two sites could not be 
separated because of their proximity so we decided to keep them together in one 
fragment. This way we were able to check the predictions of the PITA algorithm for each 
site as to the most efficient binding. 
Using the primers we amplified each of our fragments and the whole 3’ UTR and restricted 
it with specific restriction enzymes. The sites for these enzymes were chosen and 
integrated in our primers so that after digestion we would be able to ligate our PCR 
product with our vector in a given direction. 
 
Figure 23 Results of the cloning for the 3 smaller fragments of the 3'UTR of PARN. In the first three rows we have plasmids 
obtained by different colonies in the same plate for fragment 1. The fourth row is the control of the band we expect to see and 
is marked by a star. The same pattern is repeated for the next two fragments. The last two rows contain the plasmid without 
anything cloned as a control for the size of the plasmid in our samples. 
After the ligation we transformed DH5α cells and allowed them to grow overnight at 37°C 
on ampicillin plates for the selection. From these colonies we extracted the plasmid DNA 
and then digested some of it with our chosen restriction enzymes, XhoI and SacI HF®. 
The result of the digestion is loaded into a 1,5% agarose gel. In figure 23 you see the 
result of our cloning for the 3 smaller fragments of the 3’ UTR of PARN. Signed with the 
small black stars are the controls. After every three samples you see a control of the 
fragment we expect and in the last two wells we see the vector digested and non-digested 
respectively. From the image we see that the cloning probably is correct because the size 
of the bands appear to be correct. To validate our result we sent the two of the three 
samples of each fragment for sequencing. From the result of the sequencing we were able 
to validate the success of our cloning for all of the three fragments. 
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Figure 24 The chromatograph of the cloning of the first fragment that contains the site for miR-29a 
The same procedure was followed for the whole 3’ UTR of PARN. Again the result are 
visible on a 1,5% agarose gel. For the validation of the cloning success we again 
sequenced our products. In figure 26 you can see part of the chromatograph of the total 3’ 
UTR of PARN. Bioinformatic analysis of the sequence allowed us to confirm the results of 
the cloning. Again the star indicates the band that acts as a control for the band that we 
want to see cloned in our vector 
 
Figure 25 The results from the result of the restriction for the whole 3' UTR. The gel is 1,5 % agarose gel with EtBr. Marked 
by a star you can see the expected band. 
 
Figure 26 Part of the chromatograph of the PARN 3' UTR. 
 
5.3. Production of mutants for the 3’ UTR of PARN 
 
After the successful cloning of the 3’ UTR we decided to proceed also with the creation of 
mutants. These mutants would allow us to show that whatever effect we observe through 
the Luciferase assay can be inverted if we eliminate the sites for our miRNA. For this 
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reason we created mutants of the whole 3’ UTR for every one of the four sites that exist on 
our region. We also created double mutants in which we eliminated two of the sites each 
time. More specifically the two sites for miR-29a-3p or the two sites for miR-1207-5p. As 
discussed in materials and methods used specific primers for the mutagenesis. 
The results were shown using the same workflow as in cloning. First we transformed our 
cells, in this case XL-10, and allowed them to grow overnight on ampicillin plates for 
selection. The plasmid DNA was extracted and then digested with the enzymes of choice. 
The results were observed on a 1,5% agarose gel and then validated by sequencing. In 
the gel the recognition of the correct band was done only by the size indicated by the 
marker. As template for the creation of the double mutants we used the single mutants that 
we created in the first mutagenesis. 
The mutants were created using as template the total 3’ UTR and not the smaller 
fragments. This was the better choice because the size of the fragments is too small 
around 200 base pairs and the deletion of 8 base pairs seemed as a big intervention. The 
other fact is that the total 3’ UTR has a secondary structure that resembles more to the 
natural and would not be seriously affected by the deletion. In figures 27 and 28 we see 
the results from the electrophoresis of the digested mutant plasmids. 
 
Figure 27 Gel results for the mutagenesis of a single site. The gel is 1,5 % agarose gel with EtBr. There is no specific control 
other by the size of the band that is about 1000 bp. 
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Figure 28 Gel results from the mutagenesis of the double mutants. Mutagenesis did not work in the first well. The gel is 1,5 % 
agarose gel with EtBr. There is no specific control other by the size of the band that is about 1000 bp. 
 
 
 
 
 
5.4. Luciferase assay for the investigation of putative interaction 
between the 3’ UTR of PARN and miR-29a or miR-1207 
 
First we performed a Luciferase assay without introducing any part of the 3’ UTR of PARN 
cloned in our vectors. This way we checked if the overexpression of the miRNAs would 
cause any problems to the levels of the Luciferase due to possible interactions between 
the miRNAs and the endogenous PARN in HeLa. Our interest was focused on putative 
interactions of the endogenous PARN with the miRNA that could interfere in our Luciferase 
signal. These interactions could lead to the down regulation of the endogenous PARN and 
cause problems in the stability of the mRNA transcribed by the Luciferase vector, due to 
improper deadenylation of the transcript. The graph below shows that the minor 
decreases, 6-11 %, we observed were of no statistical significance. We therefore do not 
have to take into account any interference of the endogenous PARN with our miRNAs.  
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Figure 29 Luciferase assay results for the experiment used to see if the levels of the Luciferase are affected by the 
overexpression of our miRNAs in the endogenous condition. P-value was calculated using one-tailed unpaired t-test for 
samples with unequal variance. Results are derived from three biological replicates. 
Then we performed our assays using our vectors with the cloned fragments. We 
performed the assay using vectors in which we cloned either one of the fragments or the 
whole 3’ UTR and vectors containing the mutants we created. In each set of data we have 
HeLa cells that were co-transfected with the Luciferase vector with our testing region and a 
vector that overexpresses no miRNA, there is another set of cells that has been 
transfected with the overexpressing vector for the one of our miRNA of interest and finally 
cells that overexpress miR-608 which is not predicted to bind on our 3’ UTR and is used as 
a negative control. Finally all of our data have been normalized against Renilla Luciferase 
and against the negative control (miR-608). Below we present the results of the Luciferase 
assays for the fragments, the whole 3’ UTR and the mutants. 
 
Figure 30 Luciferase assay result for the first fragment normalized against the negative control. P-value was calculated using 
one-tailed unpaired t-test for samples with unequal variance. One star indicates P-value ≤ 0.05. Results are derived from 
three biological replicates. 
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Figure 31 Luciferase assay results for the second fragment compared to the negative control. P-value was calculated using 
one-tailed unpaired t-test for samples with unequal variance. Results are derived from three biological replicates. 
 
Figure 32 Luciferase assay results for the third fragment compared to the negative control. P-value was calculated using one-
tailed unpaired t-test for samples with unequal variance. One star indicates P-value ≤ 0.05. Results are derived from three 
biological replicates. 
Figures 30 to 32 show the graphic representation of our results 24 hours post transfection. 
We were able to observe a reduction in all fragments but only in two of them, fragment 1 
and 3, this reduction was statistically significant. For all the analysis of the Luciferase our 
main comparison is done between the effect of our miRNAs and the effect of miR-608. We 
made this choice because this condition seemed more close to a control since in both 
cases the cells have a miRNA overexpressed. On the contrary in the case of the use of the 
empty vector for the overexpression of miRNAs we believed that the stress of the cells is 
not equal to our case. 
In particular for fragment 1 we have a reduction of 16,9 % compared to our negative 
control. In fragment 2 we see a reduction of 17,5 % but it is not statistically significant. 
Probably this could be a condition that could be repeated to validate further the results. In 
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fragment 3 we observe the biggest reduction of all the fragments. Since in fragment 3 we 
have one position for each miRNA we tested it against both. With miR-29a we achieved a 
reduction of 23 % and with miR-1207 the effect was a bit stronger (27 %). This result drew 
our attention because the bioinformatic analysis predicted that the sites in fragments 1 and 
2 were the most prominent sites to induce an effect (minimum free energy of -24,1 
kcal/mol and -36,6 kcal/mol compared to -17,4 kcal/mol and -27,8 kcal/mol respectively). 
For us this was not the case since the biggest effect was on fragment 3 which contained 
the two least prominent sites. One reason behind it could be the fact that this fragment has 
two sites and not only one like the others and maybe the effect is somehow doubled. Also 
we have observed that the transfection of miR-1207 induces also the overexpression of 
miR-29a3p and a repression of miR-29a-5p, and, vice versa, transfection of miR-29 
induces also the overexpression of mir-1207-3p and a downregulation of miR-1207-5p, so 
probably we have a combined effect induced from both miRNAs in this case.  
Our case about the most prominent sites seems to be established we incorporated the 
data from the Luciferase assay done for the 48 hours.  
The effect seen on the 24-hour experiment for fragments 1 and 2 was lost at 48 hours 
(figures 33-34): there was no significant decrease for both of the fragments. To our 
knowledge the 48-hour time is not considered so informative. This is because 48 hours of 
miRNA overexpression can cause many changes in the cells, so it is difficult to distinguish 
the specific events. In fragment 3 we noticed that the reduction observed by the 
overexpression of miR-29a again is lifted like in the other fragments. On the contrary the 
effect observed by miR-1207 is still observed (reduction of 21 %) and even though it is not 
significant it is close to the levels of significance compared to the others (figure 35). The 
reason behind this could be again the fact that the overexpression of miR-1207 causes the 
overexpression of miR-29a in HeLa. In this way the effect is more persistent because we 
have the presence of both miRNAs and the fragment has sites for both of them allowing 
probably a synergistic effect. Of course further investigation and validation is needed for 
this hypothesis. 
Subsequently we decided to examine the 3’ UTR of PARN as a whole. For this reason we 
used Luciferase vectors with the total 3’ UTR cloned. This way we were able to use a 
system that resembles to the natural one. The total 3’ UTR adopted secondary structure 
that is definitely more close to the natural structure compared to our fragments, which 
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were only a couple hundred base pairs in length. The results are depicted in figures 36 
and 37. 
 
Figure 33 Luciferase assay results for the 48 hours compared to the negative control. P-value was calculated using unpaired 
t-test with one tail for samples with unequal variance. Results are derived from three biological replicates. 
 
Figure 34 Luciferase assay results for the 48 hours compared to the negative control. P-value was calculated using unpaired 
t-test with one tail for samples with unequal variance. Results are derived from three biological replicates. 
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Figure 35 Luciferase assay results for the 48 hours compared to the negative control. P-value was calculated using unpaired 
t-test with one tail for samples with unequal variance. Results are derived from three biological replicates. 
 
Figure 36 Luciferase assay results for the 24 hours for the whole 3' UTR of PARN. P-value was calculated using unpaired t-
test with one tail for samples with unequal variance. Two stars indicates P-value ≤ 0.01. Results are derived from three 
biological replicates. 
 
Figure 37 Luciferase assay results for the 48 hours for the whole 3' UTR of PARN. Results are derived from three biological 
replicates. 
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As depicted in figure 36, 24 hours post transfection we were able to obtain a strong 
reduction of more that 20 % with both miRNAs. In particular miR-29a caused a reduction 
of 23 % and miR-1207 one of 28 %. Even though the difference is small the stronger effect 
of miR-1207 could be because of the phenomenon we discussed earlier about the 
overexpression of this specific miRNA. When looking to the results from the 48 hours we 
noticed that the effect was lifted once again much like the results from the fragments. 
Again of course we must take into account that the 48 hour time point is enough to cause 
changes in the cell that lead to the lift of our effect in an non specific way. 
For that reason we decided to move one step further and produce mutants of the 3’ UTR. 
That way we could validate that the reduction we were able to see was not by chance but 
was due to the binding of the miRNAs. The reason we chose the whole one and not the 
fragments is simple. First of all, we wanted to allow the adoption of the closest to the 
natural secondary structure. Moreover the fragments are very small and the deletion of 
8nucleotides was not possible for us because it would reduce further their already small 
size. For that way all of the mutants are derived from the whole 3’ UTR. 
In figures 38 to 41 we compare wild type 3’ UTR to the single mutants we created for each 
of the four positions. In each graph we se the percentage of change between the wild type 
and the mutants and the statistical significance of this difference. 
 
Figure 38 Comparison of the Luciferase assay results between the wild type 3’ UTR and the mutant for the 1st site of miR-
29a. In every comparison we see the percentage of difference between the negative control and the different conditions. P-
value was calculated using unpaired t-test with one tail for samples with unequal variance. One star indicates P-value ≤ 0.05 
two stars indicates P-value ≤ 0.01. Results are derived from three biological replicates for each (wild type and mutant). 
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Figure 39 Comparison of the Luciferase assay results between the wild type 3’ UTR and the mutant for the 1st site of miR-
1207. In every comparison we see the percentage of difference between the negative control and the different conditions. P-
value was calculated using unpaired t-test with one tail for samples with unequal variance. One star indicates P-value ≤ 0.05. 
Results are derived from three biological replicates for each (wild type and mutant). 
In the graphs we can see the obvious lift of the effect of the wild type by the mutants. The 
decrease seems to be completely gone in most of the cases. It is worth mentioning 
however the fact that the decrease is lifted no mater what miRNA we overexpress with our 
mutants. This is strange as we expected that each mutant would probably resist only to the 
targeted miRNA. One possibility would be the repetition of this mutant experiment in order 
to validate even further the results and understand if this effect we see here is actually 
true. In every case we do not present the data of the 48-hour experiment with the mutants 
since there was no indication of any effect of the miRNAs on the wild type. For the first two 
mutation positions (Figure 38 & 39) we have no reduction but instead we have an 
increase. This is not expected and further experimentation is required to validate our 
results. For the mutations on the two other sites (Figures 40 & 41) we have better results. 
The changes in the Luciferase levels are no significant and very small compared to those 
observed with the wild type constructs.  
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Figure 40 Comparison of the Luciferase assay results between the wild type 3’ UTR and the mutant for the 2nd site of miR-
29a. In every comparison we see the percentage of difference between the negative control and the different conditions. P-
value was calculated using unpaired t-test with one tail for samples with unequal variance. One star indicates P-value ≤ 0.05 
two stars indicates P-value ≤ 0.01. Results are derived from three biological replicates for each (wild type and mutant). 
 
Figure 41 Comparison of the Luciferase assay results between the wild type 3’ UTR and the mutant for the 2nd site of miR-
1207. In every comparison we see the percentage of difference between the negative control and the different conditions. P-
value was calculated using unpaired t-test with one tail for samples with unequal variance. One star indicates P-value ≤ 0.05. 
Results are derived from three biological replicates for each (wild type and mutant). 
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6. Conclusions and future prospective 
 
We used overexpressing vectors containing the precursor region of miR-29a and miR-
1207. Our goal was to investigate possible interactions of the 3’ UTR of PARN and these 
specific miRNAs. Using the 3’ UTR of PARN we were able to see an interaction of the 
region with the miRNAs of interest, miR-29a and miR-1207. This interaction was seen 
using fragments of the 3’ UTR containing each time one site for one miRNA but also by 
using the total 3’ UTR. The reductions observed were strong and statistically significant. 
The construction of single mutants did show a relief of the reduction but this was not a 
specific event against a particular miRNA. In the future a Luciferase assay must be 
performed on the double mutants. The results of this experiment might enable us to clarify 
why we do not see a specific relief and shed some more light on the interactions of our 
miRNAs of interest and the PARN mRNA. Furthermore a repeatition of the Luciferase 
assays performed on the single mutants should be considered in order to validate the 
results shown in this thesis. Moreover it is important to obtain proof of the effects on the 
endogenous PARN, while over expressing the miRNAs, both in protein and mRNA levels. 
Another interesting experiment would be the use of LNA inhibitors, in Luciferase 
experiments as the ones described above, that can be used on cell lines, supposing they 
have a good basal level of expression of one of the miRNAs of interest every time, to 
sequestrate the miRNA and thus induce the opposite effect from what we observed in this 
thesis, meaning an increase of the Luciferase signal and not a reduction. This requires of 
course the discovery of cell line that shows good levels of endogenous miR-1207.  
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